Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Lallas on Immunotherapy Combinations in Genitourinary Malignancies

Costas Lallas, MD
Published: Monday, May 22, 2017



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

The checkpoint inhibitors are how the body recognizes itself, explains Lallas. Checkpoint inhibitors allow T cells to be activated, and increase cellular response against malignancies, which is a reason why immunotherapy has been efficacious.

Hypothetically, if you can combine regimens that ramp up the immune system maximally to fight these malignancies, it is going to be beneficial, states Lallas.
 


Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

The checkpoint inhibitors are how the body recognizes itself, explains Lallas. Checkpoint inhibitors allow T cells to be activated, and increase cellular response against malignancies, which is a reason why immunotherapy has been efficacious.

Hypothetically, if you can combine regimens that ramp up the immune system maximally to fight these malignancies, it is going to be beneficial, states Lallas.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x